AACR22: Bris­tol My­er­s' Op­di­vo is yet to reach sur­vival end­point in ear­ly-stage lung can­cer. But will it mat­ter?

NEW OR­LEANS — Fresh off a land­mark ap­proval for its block­buster check­point in­hibitor Op­di­vo, Bris­tol My­ers Squibb is tout­ing new da­ta at AACR it hopes will bol­ster its case for ear­ly-stage lung can­cer. But it’s un­clear whether the new sur­vival da­ta will do so, giv­en the drug has al­ready won ap­proval — and the fact it hasn’t hit sta­tis­ti­cal sig­nif­i­cance yet.

Bris­tol My­ers earned the FDA green light last month based on Op­di­vo’s sta­tis­ti­cal­ly sig­nif­i­cant re­duc­tion in event-free sur­vival com­pared to place­bo, re­duc­ing the risk of pro­gres­sion, re­cur­rence or death by 37%. The new da­ta un­veiled in New Or­leans, Op­di­vo’s sec­ondary over­all sur­vival mea­sure, did not reach sta­tis­ti­cal sig­nif­i­cance yet, how­ev­er.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER